Lupin is currently trading at Rs. 978.50, up by 18.05 points or 1.88% from its previous closing of Rs. 960.45 on the BSE.
The scrip opened at Rs. 956.50 and has touched a high and low of Rs. 979.80 and Rs. 950.70 respectively. So far 61686 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 979.80 on 28-Feb-2014 and a 52 week low of Rs. 569.00 on 01-Mar-2013.The current market cap of the company is Rs. 43826.73 crore.The promoters holding in the company stood at 46.76% while Institutions and Non-Institutions held 43.22% and 10.02% respectively.
Pharma Major Lupin has received final approval for its Rifabutin Capsules USP, 150 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Pharmacia & Upjohn Company's Mycobutin Capsules 150 mg. Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary would commence marketing the product shortly.
Lupin's Rifabutin Capsules, 150 mg are generic equivalent of Pharmacia & Upjohn Company's Mycobutin Capsules 150 mg. Lupin's Rifabutin Capsules USP, 150 mg is indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.Mycobutin Capsules had annual U.S sales of $18.6 million in 2013 (IMS MAT Dec, 2013).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
No comments:
Post a Comment